Health Condition 1: K30- Functional dyspepsia
Conditions
Interventions
Intervention1: Qurs-i-Tinkar: Form Tablet
Route of administration Oral
Dosage two tablets twice daily 250mg each with 1 glass of normal water for a period of 28 days
Follow up 0th 7th 14th 21st and 28
Sponsors
Luqman Unani Medical College Hospital and ResearchCenter
Eligibility
Inclusion criteria
Inclusion criteria: 1 Individuals of any gender aged between 18 and 40 years 2 Patients who meet the diagnostic criteria outlined in the "Rome IV" guidelines for Functional dyspepsia. These criteria require the presence of symptoms for at least three months within the past six months prior to diagnosis including experiencing one or more of the following a Bothersome postprandial fullness b Bothersome early satiation c Bothersome epigastric pain d Bothersome epigastric burning 3 Individual who is willing to provide voluntary consent
Exclusion criteria
Exclusion criteria: 1 People aged 41 years or older exhibiting symptoms including weight loss alongside dyspepsia reflux treatment-resistant dyspepsia dyspepsia with elevated platelet count nausea vomiting or low hemoglobin levels 2 Individuals of any age experiencing difficulty swallowing (dysphagia) 3 Individuals presenting with vomiting blood (hematemesis) 4 Upper abdominal mass felt on palpation 5 Any previous or family history of GI Cancer 6 Dyspepsia overlapping Irritable Bowel Syndrome (IBS) symptoms 7 Those with a known hypersensitivity to the study drug or any of its ingredients 8 Previously diagnosed cases of organic gastrointestinal diseases 9 Any previous history of abdominal surgery 10 Known case of systemic illness such as malignant hypertension diabetes mellitus cardiopulmonary diseases etc 11 Pregnant and lactating females
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Global Overall Symptom (GOS) Scale (using 7 point Likert scale, participants are asked to grade the overall severity of 10 upper gastrointestinal symptoms)Timepoint: Primary outcome will be measured at every follow up. | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall treatment effect (OTE)Timepoint: 1st, 2nd, 3rd and 4th follow up | — |
Countries
India
Contacts
Public ContactDr Saba Mamdapur
Luqman Unani Medical College Hospital and Research Centre VijayaPura Karnataka 586101
Outcome results
None listed